Systematic review on the efficacy and safety of immune checkpoint inhibition in renal cell carcinoma.

Abstract

To perform a systematic review of the relevant literature about clinical trials on efficacy and safety of immune checkpoint inhibition, whether it is used alone, in combination or with other targeted therapies in patients with advanced and metastatic renal cell carcinoma (RCC), two team members reviewed the abstracts and selected pertinent articles from the relevant databases. A narrative review of randomized controlled trials was performed and seven randomized controlled trials were identified in this systematic review. In treatment of RCC, nivolumab has superior efficacy and safety compared with second-line everolimus. Combination strategies, especially those combined with anti-VEGF agents presents better efficacy but worse outcomes in term of safety than monotherapy and conventional treatment and might guide treatment choice for patients with RCC.

• Authors: Chen Lyu, Wenyue Li, Songcai Liu, Shuang Gao, Hong Zhang, Linlin Hao, Hao Yu, Wenzhen Wei, Jie Song, Yaoyao Yang, Chunmeng Wang, Zhimin Zhang, Nan Wang
• Journal: Future oncology (London, England) (Future Oncol) Vol. 14 Issue 21 Pg. 2207-2221 (Sep 2018) ISSN: 1744-8301 [Electronic] England
• PMID: 29726696 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Antineoplastic Agents, Immunological
• Biomarkers, Tumor

Topics

• Animals
• Antineoplastic Agents, Immunological (pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Biomarkers, Tumor (antagonists & inhibitors)
• Carcinoma, Renal Cell (drug therapy, immunology)
• Clinical Trials as Topic
• Combined Modality Therapy
• Humans
• Kidney Neoplasms (drug therapy, immunology)
• Molecular Targeted Therapy
• Treatment Outcome